Cellular and Molecular Differences between HFpEF and HFrEF: A Step Ahead in an Improved Pathological Understanding.

Simmonds SJ, Cuijpers I, Heymans S, Jones EAV. · 2020

Read Cellular and Molecular Differences between HFpEF and HFrEF: A Step Ahead in an Improved Pathological Understanding. by Simmonds SJ, Cuijpers I, Heymans S, Jones EAV. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7016826.txt.

Introduction

Simmonds and co-authors review two major forms of heart failure in the journal Cells. One form keeps a normal pumping fraction but the heart relaxes poorly. The other weakens contraction itself. Drugs that help the second form have largely failed in the first, which now accounts for over half of all cases.

The review compares the two conditions at the cell and molecular level. It covers inflammation and blood-vessel function in each form. It also covers heart-muscle cell growth and death, changes in the spring-like protein titin, and scar tissue build-up. Risk profiles differ too, with age, high blood pressure, and diabetes weighing more in the preserved form. The authors map these gaps to guide the search for new treatments.

Catalog record

CREATORSimmonds SJ, Cuijpers I, Heymans S, Jones EAV.
YEAR2020
COLLECTIONPAPERS
FORMATTXT
FILE SIZE74 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7016826

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Cellular and Molecular Differences between HFpEF and HFrEF: A Step Ahead in an Improved Pathological Understanding By Steven J. Simmonds, Ilona Cuijpers, Stephane Heymans, Elizabeth A. V. Jones, Matthijs Blankesteijn Published in: Cells DOI: 10.3390/cells9010242 ABSTRACT Heart failure (HF) is the most rapidly growing cardiovascular health burden worldwide. HF can be classified into three groups based on the percentage of the ejection fraction (EF): heart failure with reduced EF (HFrEF), heart failure with mid-range—also called mildly reduced EF— (HFmrEF), and heart failure with preserved ejection fraction (HFpEF). HFmrEF can progress into either HFrEF or HFpEF, but its phenotype is dominated by coronary artery disease, as in HFrEF. HFrEF and HFpEF present with differences in both the development and progression of the disease secondary to changes at the cellular and molecular level. While recent medical advances have resulted in efficient and specific treatments for HFrEF, these treatments lack efficacy for HFpEF management. These differential response rates, coupled to increasing rates of HF, highlight the significant need to understand the unique pathogenesis of HFrEF and HFpEF. In this review, we summarize the differences in pathological development of HFrEF and HFpEF, focussing on disease-specific aspects of inflammation and endothelial function, cardiomyocyte hypertrophy and death, alterations in the giant spring titin, and fibrosis. We highlight the areas of difference between the two diseases with the aim of guiding research efforts for novel therapeutics in HFrEF and HFpEF. 1. INTRODUCTION Heart failure (HF) is the most prominent cause of hospitalization globally, with 3.6 million newly diagnosed patients annually, resulting in a socioeconomic burden of billions of euros per year [1]. Heart failure with preserved ejection fraction (HFpEF) is a complex cardiovascular syndrome presenting with an ejection fraction (EF) of greater than 50%, along with different pro-inflammatory and metabolic co-morbidities. It is characterised by structural and cellular alterations, including cardiomyocyte hypertrophy, fibrosis, and inflammation, all leading to an inability of the left ventricle to relax properly. In contrast, HFrEF, defined by an EF of less than 40%, is characterized by substantial cardiomyocyte loss, resulting in the development of systolic dysfunction; in other words, the inability of the left ventricle to contract properly. Heart failure with mid-range or mildly reduced EF (HFmrEF), is an intermediate stage, with an EF between 40–49%, that generally progresses either to HFpEF (25% of cases) or HFrEF (33% of cases) [2]. With regard to ischaemic aetiology, HFmrEF more resembles HFrEF, but HFmrEF has a higher frequency of underlying coronary artery disease (CAD) and better overall prognosis [2,3,4]. HFpEF is preceded by chronic comorbidities, such as hypertension, type 2 diabetes mellitus (T2DM), obesity, and renal insufficiency, whereas HFrEF is often preceded by the acute or chronic loss of cardiomyocytes due to ischemia, a genetic mutation, myocarditis, or valvular disease [5,6]. This alteration in risk factors already highlights the potential for differing cellular and molecular pathophysiologies of the two diseases. Medical advances have developed efficient and specific treatments of HFrEF by acting on the neuro-humoral axis, but efficacious drugs for the treatment of HFpEF are absent [7]. As a consequence, the prevalence rate of HFrEF has significantly declined over the last few decades, while the prevalence of HFpEF accounts for more than 50% of all HF cases and is expected to rise even further [8]. These differential response rates to therapies in patients with HFrEF and HFpEF underline their distinct underlying cellular and molecular mechanisms [9]. 2. DIFFERENCES IN COMORBIDITIES/RISK FACTORS IN HFREF AND HFPEF Despite the fact that acute cardiovascular events associated with HFrEF and HFpEF share many risk factors [10], some comorbidities differ between them (Table 1, Figure 1). Patients with HFpEF are more likely to be older [11], with a two-fold predominance of females [12]. This predominance of men in HFrEF might be the result of a greater susceptibility to developing myocardial infarction (MI) [11]. Additionally, men more easily develop eccentric left ventricular hypertrophy upon pressure-overload, while concentric hypertrophy is more common in females [13]. Patients with HFpEF have a higher prevalence of non-cardiac comorbidities (i.e., hypertension, T2DM, stroke, anaemia, pulmonary disease, liver disease, sleep apnoea, gout, and cancer) than HFrEF patients [14]. The mortality risk of the comorbidities studied in both types of HF is similar, regardless of the EF [15,16,17]. Interestingly, in HFpEF, the incidence of hospitalisation for comorbidity-related illness is higher compared to HFrEF [18]. 3. SYSTEMIC AND CARDIAC INFLAMMATION HAS A DIFFERENTIAL ROLE IN HFREF AND HFPEF Inappropriate or exaggerated inflammation is a key component underlying damage to the heart in both HFrEF and HFpEF, but has different roles in the onset and propagation. Depending on the trigger, the inflammatory response can be classified into three groups: sterile-, metabolic risk-, and non-sterile-induced inflammation (Table 1, Figure 2). 3.1. Sterile Inflammation Sterile inflammation occurs due to post-ischemic or toxic necrosis, massive trauma, haemorrhage, and/or resuscitation, such as in the HFrEF condition MI [76] (Figure 2). During this response, sterile endogenous stimuli trigger inflammation by a) activating the pathogen recognition receptor (PRR) pathway via the exposure to host-derived non-microbial stimuli released following tissue injury, called damage-associated molecular patterns (DAMPs; e.g., DNA, ATP, and hyaluronan), b) releasing intracellular cytokines, which activate common pathways downstream of PRRs, and/or c) triggering the activation of receptors which are not typically associated with microbial recognition, such as the cluster of differentiation 36 (CD36) [19,77]. Following ligand recognition, PRRs activate downstream signalling, such as transcription factor nuclear factor kappa-B (NFκB), mitogen-activated kinase (MAPK), and type I interferon (IFN), which upregulate pro-inflammatory cytokines and chemokines that are important in the healing response [19]. Furthermore, dying cells release molecules that break the extracellular matrix (ECM) down (matrix metalloproteinases; MMPs), oxidize macromolecules, and induce the production and release of abnormal host cell products, such as heat shock proteins (HSPs) [76,78]. In the meantime, the activation of adrenergic signalling alerts the bone marrow to reduce the production of hematopoietic stem cell (HSC) retention factors [79]. Consequently, HSC and progenitor cells are attracted from their specific niches in the bone marrow by the stromal cell-derived chemokine CXCL12, leading to the production of neutrophils, called granulopoiesis [79]. Neutrophils are rapidly released in the blood and are recruited to the heart, where they phagocytose the damaged cells. Interestingly, the serum neutrophil to lymphocyte ratio is considered a useful marker for the prediction of mortality in patients admitted for ST-segment elevation MI (STEMI) [80]. Furthermore, HSCs egress from the bone marrow and seed in the spleen, thereby triggering extramedullary hemopoiesis and monocyte production [81]. Within 24 h after MI, the splenic monocyte reservoir is released into the circulation and monocytes are recruited to the heart [82]. Monocytes subsequently infiltrate and produce cytokines and growth factors, such as IL-10 and transforming growth factor β (TGFβ), to repress inflammatory signalling, promote new blood vessel formation by endothelial cells and vascular smooth muscle cells, and scar formation by (myo)fibroblast activation [83,84]. Furthermore, B- and total and regulatory T-cells are recruited to the heart, where they modulate cardiac remodelling [19,85,86]. Regulatory T-lymphocytes have a protective role in ventricular remodelling in MI [86]. As such, the adoptive transfer of regulatory T-cells attenuates inflammation by limiting the local inflammatory response, including reducing immune cell infiltration (T-lymphocytes, macrophages and neutrophils) and pro-inflammatory cytokine production by cardiomyocytes [86]. However, the complex

Read the complete text